Mechanisms of drugs in the treatment of type 2 diabetes mellitus

Yang, Tao; Wang, Hongmei; Li, Caili; Duan, Haogang

doi:10.1097/cm9.0000000000002356

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further studies are required to describe the structural activity relationship and molecular mechanism behind the anti-obesity property of T2DM medications and the molecular modeling aspect correlating the weight loss effects of T2DM agents at the molecular level. For example, numerous studies suggested that protein tyrosine phosphatase 1B (PTP1B) inhibitors could be a promising treatment for T2DM and obesity [221,222]. Moreover, it has been demonstrated that liraglutide downregulated PTP1B which could explain its antidiabetics and anti-obesity effects [222].…”

Section: Summary Conclusion and Future Directionsmentioning

confidence: 99%

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications

Haddad

Dokmak

Bader

2023

Life

View full text Add to dashboard Cite

Obesity is a complex metabolic condition that can have a negative impact on one’s health and even result in mortality. The management of obesity has been addressed in a number of ways, including lifestyle changes, medication using appetite suppressants and thermogenics, and bariatric surgery for individuals who are severely obese. Liraglutide and semaglutide are two of the five Food and Drug Administration (FDA)-approved anti-obesity drugs that are FDA-approved agents for the treatment of type 2 diabetes mellitus (T2DM) patients. In order to highlight the positive effects of these drugs as anti-obesity treatments, we analyzed the weight loss effects of T2DM agents that have demonstrated weight loss effects in this study by evaluating clinical studies that were published for each agent. Many clinical studies have revealed that some antihyperglycemic medications can help people lose weight, while others either cause weight gain or neutral results. Acarbose has mild weight loss effects and metformin and sodium-dependent glucose cotransporter proteins-2 (SGLT-2) inhibitors have modest weight loss effects; however, some glucagon-like peptide-1 (GLP-1) receptor agonists had the greatest impact on weight loss. Dipeptidyl peptidase 4 (DPP-4) inhibitors showed a neutral or mild weight loss effect. To sum up, some of the GLP-1 agonist drugs show promise as weight-loss treatments.

show abstract

Section: Summary Conclusion and Future Directionsmentioning

confidence: 99%

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications

Haddad

Dokmak

Bader

2023

Life

View full text Add to dashboard Cite

show abstract

Treatment modification patterns of glucose-lowering agents in Saudi Arabia: A retrospective real-world data analysis

Alfakhri,

Almadani,

Althunian

et al. 2024

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Therapeutic Charisma of Imidazo [2,1-b] [1,3,4]-Thiadiazole Analogues: A Patent Review

Mehra,

Sangwan,

Mehra

et al. 2023

Pharm. Pat. Anal.

View full text Add to dashboard Cite

Imidazothiadiazole was discovered around the 1950s era, containing an imidazole ring fused to a thiadiazole ring. Imidazothiadiazole exhibit versatile pharmacological properties including anticonvulsant, cardiotonic, anti-inflammatory, diuretic, antifungal, antibacterial and anticancer. Despite of the being discovered in 1950s, the imidazothiadiazole derivatives are unable to being processed to clinical trials because of lack of bioavailability, efficacy and cytotoxicity. The recent patent literature focused on structural modification of imidazothiadiazole core to overcome these problems. This review limelight a disease-centric perspective on patented imidazothiadiazole from 2015–2023 and to understand their mechanism of action in related diseases. The relevant granted patent applications were located using patent databases, Google Patents, USPTO, EPO, WIPO, Espacenet and Lens.

show abstract

Mechanisms of drugs in the treatment of type 2 diabetes mellitus

Cited by 3 publications

References 22 publications

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications

Treatment modification patterns of glucose-lowering agents in Saudi Arabia: A retrospective real-world data analysis

Therapeutic Charisma of Imidazo [2,1-b] [1,3,4]-Thiadiazole Analogues: A Patent Review

Contact Info

Product

Resources

About